Quick answer: NAD+ (nicotinamide adenine dinucleotide) is the central redox coenzyme participating in over 500 enzymatic reactions and the essential substrate for sirtuins (epigenetic regulators), PARP DNA repair enzymes, and CD38 calcium signaling — all of which decline with aging. NAD+ tissue levels fall 50% between ages 30 and 70 (Massudi 2012). NMN (nicotinamide mononucleotide) at 250mg/day raised NAD+ levels significantly and improved muscle insulin signaling in a 10-week placebo-controlled RCT in postmenopausal women (Yoshino 2021, Science). NR (nicotinamide riboside) at 300mg/day raises blood NAD+ 40-90% within 2-4 weeks across multiple human trials. The CD38 inhibitors apigenin (50mg/day) and quercetin (500mg/day) reduce the primary enzyme responsible for age-related NAD+ degradation.
NAD+: The Central Coenzyme of Cellular Energy and Longevity
Nicotinamide adenine dinucleotide (NAD+) is one of the most abundant and functionally critical small molecules in human biology. In its oxidized form (NAD+) and reduced form (NADH), it serves as the electron carrier in glycolysis, the citric acid cycle, and the mitochondrial electron transport chain — accepting electrons during substrate catabolism and donating them at Complex I of the respiratory chain, driving ATP synthesis. This classical metabolic role alone would justify NAD+’s importance, but its significance extends far beyond redox chemistry.
NAD+ is uniquely consumed (not just recycled) in its roles as a co-substrate for three classes of enzymes critical to aging biology. Sirtuins (SIRT1-7) are NAD+-dependent protein deacetylases and ADP-ribosyltransferases that regulate gene expression, DNA repair, mitochondrial biogenesis, and metabolic homeostasis — using NAD+ as a consumable co-substrate in every deacetylation reaction. PARPs (poly ADP-ribose polymerases) are NAD+-dependent DNA repair enzymes — PARP1 alone can consume enormous amounts of NAD+ during DNA damage responses, creating a competition between DNA repair and sirtuin activity for the same NAD+ pool. CD38 is an ecto-enzyme and NAD+ glycohydrolase that cleaves NAD+ to produce nicotinamide and cyclic ADP-ribose (a calcium signaling messenger) — representing the primary constitutive NAD+ consumption pathway in most mammalian tissues.
The Age-Related NAD+ Decline: Mechanism and Consequences
NAD+ tissue levels fall by approximately 50% between the ages of 30 and 70 — a decline documented in muscle, liver, brain, skin, and adipose tissue across multiple species including humans (Massudi 2012, PLoS ONE; Camacho-Pereira 2016, Cell Metabolism). This is not a trivial change: it represents a functional shift from the NAD+:NADH ratios and absolute NAD+ concentrations required for full sirtuin, PARP, and mitochondrial activity to levels at which these pathways become substrate-limited.
The primary driver of age-related NAD+ decline was identified by Camacho-Pereira and colleagues (2016, Cell Metabolism) as CD38 — specifically, the dramatic increase in CD38-expressing immune cells (macrophages and other innate immune cells) in aging tissues, driven by chronic low-grade inflammation (inflammaging). These senescence-associated and inflammation-activated immune cells express high levels of CD38, degrading the tissue NAD+ pool faster than biosynthesis can replace it. CD38 activity in aged mouse muscle is elevated approximately 3-fold compared to young muscle — sufficient to reduce NAD+ below the threshold required for full SIRT3 mitochondrial activity. This is the molecular connection between chronic inflammation and accelerated mitochondrial aging: inflammaging → CD38 upregulation → NAD+ depletion → sirtuin inactivity → mitochondrial dysfunction and epigenetic dysregulation.
The sirtuin consequence of NAD+ depletion is multifactorial. SIRT1 (nuclear) deacetylates PGC-1α (activating mitochondrial biogenesis and OXPHOS gene expression), p53 (regulating apoptosis), NF-κB (suppressing inflammatory gene expression), and FOXO3 (activating stress resistance genes). When SIRT1 is NAD+-limited, all these functions are impaired simultaneously. SIRT3 (mitochondrial matrix) deacetylates and activates SOD2 (manganese superoxide dismutase), IDH2 (reducing mitochondrial NADPH), and Complex I subunits — maintaining mitochondrial ROS defense and electron transport efficiency. SIRT6 (nuclear) is essential for telomere maintenance and genomic stability through NAD+-dependent ADP-ribosylation of histones at DNA double-strand breaks. The comprehensive picture: NAD+ depletion doesn’t cause one aging phenotype — it simultaneously impairs mitochondrial function, DNA repair, epigenetic regulation, and inflammatory control through the shared sirtuin substrate limitation.
The PARP Competition: DNA Damage and NAD+ Depletion
PARP1 (poly ADP-ribose polymerase 1) repairs DNA single-strand and double-strand breaks by synthesizing poly-ADP-ribose chains on damaged DNA — each chain consuming one NAD+ molecule. PARP1 activation can consume NAD+ at rates orders of magnitude faster than normal cellular NAD+ utilization: a single PARP1 activation event can deplete local nuclear NAD+ pools by 80% within minutes. In young cells with abundant NAD+, this rapid PARP1 activation efficiently repairs DNA damage without meaningfully affecting sirtuin activity. In aged cells with already-depleted NAD+, PARP1 activation creates a triage situation: NAD+ is diverted to emergency DNA repair at the expense of SIRT1 and SIRT6 activity — leaving epigenetic regulation and long-term genomic stability to deteriorate.
David Sinclair’s group at Harvard has documented the PARP-sirtuin NAD+ competition extensively. The 2013 Cell paper (Gomes 2013) demonstrated that NMN administration in aged mice (22 months) restored muscle NAD+ levels to those of young mice (6 months) within one week, with simultaneous restoration of SIRT1 activity markers (PGC-1α acetylation, mitochondrial gene expression, respiratory capacity), insulin sensitivity, energy metabolism, and physical activity levels. Sinclair described this as “physiological age reversal” — not lifespan extension but restoration of youthful function in aged tissue through a single molecular intervention targeting the NAD+ substrate limitation. This paper generated enormous scientific and public interest and launched the NMN supplementation industry.
NMN: Clinical Evidence in Humans
The most important NMN human RCT to date is the Yoshino 2021 Science paper — a double-blind, placebo-controlled trial of 250mg NMN/day for 10 weeks in 25 postmenopausal women with prediabetes or normal glucose but overweight status (mean age 55). NMN significantly increased skeletal muscle NAD+ metabolome (measured by NAD+ and its related metabolites in muscle biopsy), significantly improved muscle insulin signaling (specifically insulin-stimulated glucose disposal and phosphorylation of insulin signaling proteins Akt and mTOR), and improved physical performance on a 6-minute walk test. This was the first human RCT demonstrating that oral NMN raises intracellular NAD+ in a target tissue (not just blood) and produces a metabolically meaningful outcome. The 250mg/day dose is well within the practical supplemental range.
The Yamaguchi 2022 trial (n=108 older adults, 100mg NMN/day vs placebo, 12 weeks) found significant improvement in gait speed — a validated functional aging biomarker — in the NMN group versus placebo, with no significant adverse events. Liao 2021 (China, n=80, 300mg NMN/day, 60 days) confirmed safety and tolerability of oral NMN at supplemental doses, with expected NAD+ elevation in blood. Multiple Japanese industry-sponsored trials have confirmed blood NAD+ elevation at doses of 125-250mg/day NMN. A 2023 Nutrients systematic review of 9 human NMN trials found consistent NAD+ elevation, improved metabolic markers, and no concerning safety signals across doses up to 1,200mg/day in a 4-week safety trial.
NR (Nicotinamide Riboside): The Alternative Precursor
NR (nicotinamide riboside) is the other major orally available NAD+ precursor. It enters cells through nucleoside transporters and is phosphorylated intracellularly to NMN (by NRK1/NRK2 kinases), then to NAD+ by NMNAT enzymes. NR became commercially available before NMN and has a larger body of human clinical evidence given its earlier entry into the market.
Key NR human trials: Airhart 2017 (Washington University, n=12 healthy adults, 100-300-1,000mg NR single doses — dose-dependent NAD+ increase in blood); Trammell 2016 (ChromaDex-sponsored, n=12, 300mg NR — peak blood NAD+ increase approximately 90% at 2.7 hours, sustained elevation over 24 hours); Dollerup 2018 (n=40 obese adults, 1g NR twice daily for 12 weeks — significant blood NAD+ increase, no significant metabolic changes, possibly underpowered for metabolic endpoints); Elhassan 2019 (elderly subjects, NR 1g/day 21 days — significant NAD+ elevation in blood and skeletal muscle NAD+ metabolites). The consistent finding across NR trials: 300-1,000mg/day reliably and dose-dependently elevates blood NAD+ by 40-90%, with well-characterized safety at these doses. Metabolic endpoints (insulin sensitivity, lipid profiles) are inconsistently significant across trials — possibly due to insufficient dosing duration, heterogeneous populations, or the need for higher baseline NAD+ deficit in study populations.
NMN vs NR — the practical comparison: NMN requires extracellular dephosphorylation to NR before intestinal absorption (in most tissues) OR direct transport via the Slc12a8 transporter identified in mouse jejunum (Chen 2021) whose human homologue’s activity remains under investigation. NR is directly absorbed via nucleoside transporters. For most supplementation purposes, both precursors produce comparable NAD+ elevation at appropriate doses (250mg NMN ≈ 300mg NR for blood NAD+ elevation based on comparative pharmacokinetic data). NMN has the advantage of the muscle-specific insulin signaling data from Yoshino 2021; NR has the advantage of more extensive human safety data accumulated over more years. Both are appropriate NAD+ precursor choices.
CD38 Inhibition: The Overlooked Amplifier
If CD38 is the primary driver of NAD+ decline with aging, inhibiting CD38 is as logical as supplementing NAD+ precursors — and the two approaches are additive. Several naturally occurring flavonoids potently inhibit CD38. Apigenin (present in parsley, chamomile, and celery at low concentrations) has the strongest CD38 inhibitory activity of any dietary compound studied: Escande 2013 (Cell Metabolism) demonstrated that apigenin treatment of aged mice raised liver NAD+ levels by 50% and restored metabolic function comparably to NR supplementation — through CD38 inhibition rather than precursor supplementation. The effective apigenin concentration in tissue requires supplementation (50-100mg/day) beyond what food provides.
Quercetin and luteolin are additional CD38 inhibitors with documented activity in vitro and animal models. The senolytic combination of quercetin (500mg) + dasatinib is being studied for senescent cell clearance — relevant because senescent cells upregulate CD38, and their clearance would reduce the primary CD38 source driving tissue NAD+ degradation. The practical “NAD+ stack” combining a precursor (NMN or NR) with a CD38 inhibitor (apigenin) addresses both the supply and the demand side of the NAD+ equation simultaneously — producing greater NAD+ elevation than either alone.
Resveratrol and Sirtuin Activation: The SIRT1 Amplifier
Resveratrol (3,5,4′-trihydroxystilbene) was the first identified sirtuin-activating compound (STAC), discovered by Dr. David Sinclair’s group in 2003. It functions as an allosteric SIRT1 activator — reducing the Km of SIRT1 for NAD+ and acetylated substrate, effectively making SIRT1 more active at any given NAD+ concentration. This is synergistic with NAD+ precursor supplementation: NMN/NR raises the NAD+ level (substrate); resveratrol increases SIRT1’s catalytic efficiency at that elevated NAD+ level. Sinclair has described the combination as analogous to “filling a car’s gas tank and also installing a more efficient engine.”
The critical practical point about resveratrol: its bioavailability is extremely poor when taken fasted or with water. Resveratrol is fat-soluble and undergoes extensive first-pass hepatic and intestinal sulfation/glucuronidation that dramatically reduces circulating free resveratrol. Taking resveratrol with a fat-containing food increases bioavailability 4-5 fold. Micronized resveratrol formulations, pterostilbene (a dimethyl ether of resveratrol with higher oral bioavailability), and liposomal resveratrol address the absorption problem. The effective dose for SIRT1 activation in humans is estimated at 500-1,000mg/day of standard resveratrol taken with fat, based on pharmacokinetic modeling from the Sinclair lab.
Practical NAD+ Protocol and Dosing
The evidence-based NAD+ supplementation protocol for aging adults combines precursor supplementation with CD38 inhibition and SIRT1 amplification. Core protocol: NMN 250-500mg/day OR NR 300-600mg/day (both taken with food — fat-soluble cofactors enhance absorption); apigenin 50-100mg/day (CD38 inhibitor, taken with the same meal); resveratrol 500mg/day with fat-containing food (SIRT1 activator); magnesium glycinate 300-400mg at bedtime (SIRT3 and mitochondrial cofactor).
Timing considerations: NMN and NR are typically taken in the morning with breakfast, as elevated NAD+ supports morning energy metabolism and the circadian NAD+ oscillation is highest in the active phase. Some practitioners recommend taking NAD+ precursors with sirtuins’ dietary activators (quercetin, berberine from our berberine protocol) for additive AMPK-sirtuin signaling. Intermittent fasting synergizes with NAD+ supplementation: fasting activates AMPK → phosphorylates NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway) → increases endogenous NAD+ synthesis; this endogenous production is amplified by exogenous precursor supplementation. The intermittent fasting hormone protocols we’ve previously discussed therefore directly support NAD+ metabolism.
Connection to mitochondrial dysfunction: NAD+ is the essential substrate for Complex I (which oxidizes NADH to NAD+, driving proton pumping and ATP synthesis). In mitochondrial dysfunction, impaired Complex I activity leads to NADH accumulation and NAD+ depletion — a feedback loop where mitochondrial dysfunction worsens the very NAD+:NADH ratio required for Complex I to function. NAD+ precursor supplementation can break this cycle by replenishing the oxidized NAD+ pool available for Complex I.
Frequently Asked Questions
Is NMN or NR better for raising NAD+?
Both NMN and NR reliably raise blood and tissue NAD+ at appropriate doses, and neither is definitively superior for most adults. NMN has the advantage of the Yoshino 2021 Science RCT demonstrating improved muscle insulin signaling specifically — the most clinically meaningful human outcome data for any NAD+ precursor to date. NR has the advantage of more years of human safety data and a larger body of pharmacokinetic trials establishing dose-response relationships. A practical comparison: 250mg NMN/day ≈ 300mg NR/day for blood NAD+ elevation. NMN is somewhat more expensive per milligram; NR is less expensive but requires a higher total dose for comparable effect. The Slc12a8 transporter question — whether NMN has a direct intestinal absorption pathway without conversion to NR first — remains incompletely resolved for humans. For most supplementation purposes, both are appropriate choices; the preference should be guided by clinical trial data for the specific outcome you’re targeting (NMN for muscle insulin sensitivity, NR for the broader safety dataset).
Does NMN actually work in humans?
Yes — with appropriate precision about what “work” means. NMN reliably raises NAD+ in human blood and (per the Yoshino 2021 muscle biopsy data) in skeletal muscle tissue at 250mg/day. It has been shown to improve muscle insulin signaling in premenopausal women with prediabetes (Yoshino 2021), improve walking speed in older adults (Yamaguchi 2022), and is well-tolerated at doses up to 1,200mg/day in short-term safety trials. What NMN has not yet demonstrated in large, adequately powered human RCTs: lifespan extension, prevention of specific age-related diseases, or reversal of established metabolic disease. These limitations reflect the early stage of human NAD+ research rather than evidence of inefficacy. The mechanistic evidence (aging → NAD+ decline → sirtuin inactivity → mitochondrial dysfunction and DNA repair failure) is extremely well-supported, and the human pharmacokinetic and early efficacy data are consistently positive. NMN “works” in the sense of doing what it’s supposed to do biochemically; the full clinical significance will be established over the next decade of trials.
What are the side effects of NMN supplementation?
NMN is well-tolerated in human trials at doses of 100-1,200mg/day. The most commonly reported side effects are mild and transient: nausea, bloating, or gastrointestinal discomfort, particularly at higher doses and when taken on an empty stomach. Starting at 125-250mg/day with food and titrating upward as tolerated minimizes GI symptoms. Some individuals report flushing at high doses, though this is less pronounced than the flushing associated with nicotinic acid (niacin). NMN metabolizes to nicotinamide (NAM) — which at very high levels can inhibit sirtuins (NAM is an end-product inhibitor of SIRT1). This theoretical concern about “NAM feedback inhibition of sirtuins” at very high NMN doses (above 1,000mg/day) is the basis for some practitioners preferring lower doses combined with CD38 inhibitors over high-dose NMN alone. Individuals on immunosuppressive medications or with active cancer diagnoses should consult their physician, as NAD+ elevation theoretically supports immune cell proliferation.
Can you increase NAD+ without supplements?
Yes — multiple lifestyle interventions raise NAD+ through endogenous synthesis pathways. Exercise is the most potent: Zone 2 aerobic exercise activates AMPK, which phosphorylates and activates NAMPT (nicotinamide phosphoribosyltransferase) — the rate-limiting enzyme in the NAD+ salvage pathway converting nicotinamide back to NMN and NAD+. Multiple studies confirm that exercise increases skeletal muscle NAD+ by 50-100% in sedentary individuals. Intermittent fasting and caloric restriction similarly activate AMPK and NAMPT, raising NAD+ during fasting states. Heat exposure (sauna) activates heat shock proteins that support NAMPT function. Reducing inflammation — through the 5R gut protocol, anti-inflammatory diet, and sleep optimization — reduces CD38 upregulation and slows the primary NAD+ degradation pathway. For most people, combining lifestyle interventions (exercise, intermittent fasting, sleep) with modest supplemental NMN/NR provides greater NAD+ restoration than either alone, while the lifestyle practices also address the upstream drivers of NAD+ depletion.
NAD+ represents one of the most actionable and evidence-supported molecular targets in longevity medicine — with established mechanisms of age-related decline, validated human pharmacokinetics for oral precursor supplementation, and growing clinical evidence for metabolic and functional benefits. If you would like a personalized assessment of your NAD+ status and a comprehensive longevity supplement protocol, contact our office at (810) 206-1402 to schedule a consultation.